TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
Stopped early · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of TP-38 toxin administered directly into the brain and to see how well it works in treating young patients with recurrent or progressive supratentorial high-grade glioma.
Key facts
- Study ID
- NCT00074334
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 3
- Starts
- 2004-05-01
- Expected to finish
- 2006-06-01
- Last updated by the study team
- 2009-10-21
Who can join
Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Children's Memorial Hospital - Chicago — Chicago, Illinois, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.